The benefits of Crospon’s EndoFLIP® system presented at International Obesity Surgery Congress 2010
Study highlights significant improvement in early weight loss after gastric band surgery
Thursday 9th September 2010
Crospon, an Irish medical device developer based in Galway, has announced results of a study presented at the 15th Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO 2010), in Long Beach, CA.
The study which took place at the Speciality Surgery Center of Fort Worth, TX, a Center of the
AIGB True Results clinical network, the largest gastric band placement network in the world,
under the direction of Principal Investigator Dr. Robert G. Snow, demonstrated that 30% of the
patients measured achieved greater than 30% excess weight loss in the 4-6 week period after
surgery. Even though they had a band adjustment during surgery, no patient required their
band to be loosened in the post-operative period.
Crospon develops leading edge minimally invasive medical devices for monitoring, diagnosis and
therapy in the gastroenterology area. Earlier this year Crospon launched its EndoFLIP® product
in the U.S. market at the 12th World Congress of Endoscopic Surgery in National Harbor,
Washington DC. The EndoFLIP® product which received FDA clearance in December 2009 is the
first product of its kind, which allows a bariatric surgeon to measure and set a consistent gastric
band stoma size during surgery.
Commenting, Dr. Robert Snow, Principal Investigator said, “The results of this study are
changing the way we look at adjusting bands, in that we are no longer waiting until a month
after surgery for the patient’s first band adjustment, so that they are now getting on a more
aggressive weight loss trajectory straight after surgery. It is generally accepted that early
weight loss is a good indicator for longer term success.”
Dr Snow continued, “Further studies are planned to assess whether the EndoFLIP® system can
be used in a similar manner for post-operative band adjustment with a goal of reducing the
number of adjustments by targeting a more precise adjustment each time”.
Speaking at the Congress, Larry Fulton, VP Sales for the Americas, Crospon said, “We are
encouraged by the results of this study, and are currently introducing EndoFLIP® in a number of
other leading gastric band centers. This study has shown how gastric band surgery can be
improved to get patients losing weight more quickly by bringing science to the band adjustment
procedure. Whereas the study used the Allergan LapBand®, the EndoFLIP® may be used with any gastric band. The study clearly demonstrated that improved early weight loss was achieved,
but it remains to be seen if this translates into long term weight loss outcomes”.